Broad-Spectrum Antiviral Drug HSRx 431™ Tests Effective Against Zika Virus
TUCSON, Arizona, Sept. 6, 2016 /PRNewswire/ -- HSRx Biopharmaceutical, a leading developer of polyfunctional-powered combination drugs for infectious and age-related chronic disease conditions, confirmed its orally administered broad-spectrum antiviral drug candidate, HSRx 431™, is effective against the Zika virus. HSRx expects to begin human trials early in 2017 and will seek accelerated drug approval from the U.S. Food & Drug Administration.
Photo - http://photos.prnewswire.com/prnh/20160905/404133
Logo - http://photos.prnewswire.com/prnh/20160905/404112LOGO
Screening studies conducted by SRI International in their Shenandoah Valley facilities confirmed the effectiveness of HSRx 431 against the Zika virus. Previously conducted in vivo studies demonstrated the drug candidate's safety and effectiveness against dengue and chikungunya infections. Additional studies on HSRx 431 for Zika will be conducted in parallel by SRI International. Concurrently, the development of clinical protocols and FDA registration will be completed for Zika human safety trials.
Zika virus disease, for which the World Health Organization reports there is no vaccine or drug treatment, is transmitted primarily by Aedes aegypti mosquitoes, which are present in the Americas, Africa, the Caribbean, Asia and the Pacific. Florida, with hundreds of Zika cases, and Puerto Rico, with 5,000, are especially vulnerable. The U.S. Centers for Disease Control (CDC) advises that the Aedes mosquito is present in some 30 states, and Anthony Fauci, M.D., director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), notes that 25% of Puerto Rico's population of 3.55 million can be expected to contract Zika over the next year.
Dr. Fauci and NIAID Senior Scientific Advisor David M. Morens, M.D., wrote in the New England Journal of Medicine: "With respect to treatment, the arbovirus pandemics suggest that the one-bug-one-drug approach is inadequate; broad-spectrum antiviral drugs effective against whole classes of viruses are urgently needed."
HSRx Director of Biology Joshua Costin, Ph.D., a virologist, said HSRx 431 is designed to meet that need, which, he notes, "is timely for an additional reason: Any Zika vaccine approval could be complicated and delayed if new research findings on the Zika/dengue virus connection prove accurate." Dr. Fauci has said, "The earliest we'll have a vaccine, at best if everything works, will be some time in 2018."
Antibodies generated by infection usually provide immunity against subsequent infection, but antibody dependent enhancement (ADE), first reported as a theory by Scott Halstead, M.D., a leading authority on viruses spread by mosquitoes, allows the dengue virus to deliver follow-on infections in which antibodies actually magnify the severity of illness. Recently completed research shows human serum containing dengue antibodies enhances Zika infection 200-fold. The CDC advises that more than a third of the world's population lives in areas at risk for dengue, and 400 million additional people are infected annually. Dengue is endemic in Puerto Rico, Latin America, Southeast Asia, the Pacific Islands, the Caribbean Islands, and like Zika, is expected soon to cause widespread infection in the U.S.
HSRx Chief Executive Officer Thomas Sullivan, Jr., explained, "We patented HSRx 431 alone and in combination with Oseltamivir (Tamiflu™) and other antivirals, enabling it to become the broad spectrum antiviral drug of choice for the early treatment and prevention of a wide variety of viral infections, including Zika, dengue, chikungunya and influenza, without the need to identify the causative agent. The CDC advises that 'millions of people are sickened, hundreds of thousands are hospitalized and tens of thousands of people die from flu every year in the U.S. Combining HSRx 431 and Oseltamivir will produce a globally needed, orally-delivered, broad-spectrum antiviral drug with long shelf life and long patent life."
About HSRx Biopharmaceutical
HSRx Biopharmaceutical is an Arizona-based biopharmaceutical company that is a leader in the development of polyfunctional pharmaceuticals, a new advancement in drug treatment therapies. HSRx's combination drugs uniquely target and engage multiple molecular targets within the human body known to be involved in a disease condition - an advancement that, in contrast to the current drug treatment therapy strategy of a single molecule-single target treatment, treats the entire disease not simply a single disease symptom. HSRx utilizes a proprietary technology to identify and capture the polyfunctional disease-fighting phytonutrients in GRAS status foods and combines these proprietary compounds with leading FDA-approved generic drugs to create powerful new combination drugs with long patent lives. In clinical studies comparing the safety and effectiveness of HSRx combination drugs with current leading generic drug treatments, HSRx combination drugs demonstrate superior effectiveness and fewer reported side effects. More information is available at HSRxBiopharmaceutical.com.
Contact: Matt Russell Russell Public Communications (520) 232-9840 firstname.lastname@example.org